<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39326494</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1437-7780</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</Title><ISOAbbreviation>J Infect Chemother</ISOAbbreviation></Journal><ArticleTitle>Tocilizumab in combination with standard of care in patients with severe COVID-19 pneumonia: Efficacy and safety from a phase 3 clinical trial in Japan.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1341-321X(24)00265-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jiac.2024.09.013</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Coronavirus disease 2019 (COVID-19) is characterized by high interleukin-6 levels. Clinical data supporting tocilizumab, a monoclonal antibody that targets interleukin-6 receptor-alpha, for treating Japanese patients with severe COVID-19 pneumonia are needed.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This single-arm phase 3 study investigated tocilizumab (8 mg/kg) plus standard of care (SOC) in Japanese patients hospitalized with severe COVID-19 pneumonia. Clinical status was assessed using a 7-category ordinal scale on day 28 (primary endpoint) and day 14 (secondary endpoint). Other secondary endpoints were time to improvement (≥2 category improvement) and time to hospital discharge. Safety was assessed as the incidence of adverse events (AEs).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 48 patients enrolled, 44 (91.7 %) scored ≥3 on the 7-category ordinal scale at baseline. At day 28, 35 patients (72.9 %) scored 1 and 5 (10.4 %) scored 7 on the 7-category ordinal scale; 36 (75.0 %, 95 % confidence interval [CI]: 60.40 %-86.36 %) and 39 (81.3 %, 95 % CI: 67.37 %-91.05 %) patients achieved ≥2- and ≥1-category improvement, respectively; 6 patients (12.5 %, 95 % CI: 4.73 %-25.25 %) demonstrated ≥1-category worsening. At day 14, 25 (52.1 %, 95 % CI: 37.19 %-66.71 %) and 33 patients (68.8 %, 95 % CI: 53.75 %-81.34 %) achieved ≥2- and ≥1-category improvement, respectively; 5 patients (10.4 %, 95 % CI: 3.47 %-22.66 %) demonstrated ≥1-category worsening. Median times (95 % CI) to improvement and hospital discharge were 11 (9-15) and 15 (11-18) days, respectively. Forty patients (83.3 %) experienced AEs; the incidence of ≥grade 3 AEs was 25 %.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Tocilizumab plus SOC may provide improved clinical status in Japanese patients with severe COVID-19 pneumonia; no new safety signals were identified.</AbstractText><CopyrightInformation>Copyright © 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Nobuyoshi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, St. Luke's International Hospital, Tokyo, Japan. Electronic address: morinob@luke.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nanki</LastName><ForeName>Toshihiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirakawa</LastName><ForeName>Akihiro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamato</LastName><ForeName>Masaya</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine and Infectious Diseases, Rinku General Medical Center, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaneko</LastName><ForeName>Yuko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shiokawa</LastName><ForeName>Rie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozaki</LastName><ForeName>Ryoto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawabata</LastName><ForeName>Norihiro</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohmagari</LastName><ForeName>Norio</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Infect Chemother</MedlineTA><NlmUniqueID>9608375</NlmUniqueID><ISSNLinking>1341-321X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">COVID-19 pneumonia</Keyword><Keyword MajorTopicYN="N">Clinical trial</Keyword><Keyword MajorTopicYN="N">Interleukin-6</Keyword><Keyword MajorTopicYN="N">Severe acute respiratory syndrome coronavirus 2</Keyword><Keyword MajorTopicYN="N">Tocilizumab</Keyword></KeywordList><CoiStatement>Declaration of competing interest AH discloses consulting fees from Chugai Pharmaceutical Co. Ltd and Kowa Company Ltd. MY, NO, YK, and NM disclose research grants from Chugai Pharmaceutical Co. Ltd. MY and YK provided honoraria lectures for Chugai Pharmaceutical Co. Ltd. NM provided honoraria lectures for MSD, Shionogi Inc., Asahi Kasei Pharma, and Zeria Pharmaceutical Co., Ltd. NK, RS, and RO are employees of Chugai Pharmaceutical Co. Ltd. TN discloses consulting fees from Chugai Pharmaceutical Co. Ltd and research grants from Chugai Pharmaceutical Co. Ltd, Eli Lilly Japan K.K., and Shionogi &amp; Co., Ltd, and provided honoraria lectures for Chugai Pharmaceutical Co. Ltd, Eli Lilly Japan K.K., AstraZeneca K.K., GlaxoSmithKline Plc, and Pfizer Japan Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39326494</ArticleId><ArticleId IdType="doi">10.1016/j.jiac.2024.09.013</ArticleId><ArticleId IdType="pii">S1341-321X(24)00265-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle>